Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Northstar Gold Signs MOU with Hunan Nonferrous Ltd. to Develop Gold Resource (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Healthcare Biotechnology
Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Oncolytics Biotech Inc > AstraZeneca posts ADC wins at SABCS in breast cancer
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(5636)
•••
Comment by Noteableon Dec 09, 2022 11:43am
172 Views
Post# 35161819

RE:AstraZeneca posts ADC wins at SABCS in breast cancer

RE:AstraZeneca posts ADC wins at SABCS in breast cancerDecember 09, 2022 -  Daiichi Sankyo and AstraZeneca’s TROP2 directed ADC showed an objective response rate of 32% and a manageable safety profile in patients with metastatic TNBC in TROPION-PanTumor01 phase 1 trial.

Datopotamab deruxtecan plus durvalumab (Astrazeneca's PD-1 checkpoint inhibitor) results dmonstrated an objective response rate of 73.6% in first-line treatment of patients with metastatic TNBC in BEGONIA phase 1b/2 trial

Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) being jointly developed by Daiichi Sankyo

Enhertu (trastuzumab deruxtecan), is a HER2-directed ADC, AstraZeneca and Daiichi Sankyo to treat HER2-positive and HER2-low metastatic breast cancer.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities